Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.
Eames
Tatiana
T
Kroth
Julia
J
Flaig
Michael J
MJ
Ruzicka
Thomas
T
Wollenberg
Andreas
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D000068818:Cetuximab; D002610:Cheek; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D006801:Humans; D009333:Neck; D000077544:Panitumumab; D012867:Skin / Q000187:drug effects / Q000473:pathology; D014973:Xanthomatosis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab